Fig. 1From: Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective studyRepresentative CT scanning result of one patient with acquired MET amplification who responded to crizotinib monotherapy. a Before treatment; b partial response was detected after 1 month of treatmentBack to article page